Online inquiry

IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8959MR)

This product GTTS-WQ8959MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IL1RL2 gene. The antibody can be applied in Lymphoproliferative disease research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Corynebacterium diphtheriae; Homo sapiens
RefSeq NM_001351446.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8808
UniProt ID Q9HB29
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ8959MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8671MR IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HuMax-CD38
GTTS-WQ10889MR IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MABp1
GTTS-WQ5180MR IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CAT-354
GTTS-WQ11182MR IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MEDI0562
GTTS-WQ7676MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA GEN3013
GTTS-WQ9276MR IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMMU-132
GTTS-WQ13526MR IVTScrip™ mRNA-Anti-MCAM, PRX-003(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PRX-003
GTTS-WQ10952MR IVTScrip™ mRNA-Anti-HAVCR2, MBG-453(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MBG-453
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW